Fenaille François, Le Mignon Maxime, Groseil Catherine, Ramon Christine, Riandé Sandrine, Siret Laurent, Bihoreau Nicolas
Laboratoire français du Fractionnement et des Biotechnologies, Développement Biopharmaceutique, 3 avenue des Tropiques, BP305 Les Ulis, 91958 Courtaboeuf cedex, France.
Glycobiology. 2007 Sep;17(9):932-44. doi: 10.1093/glycob/cwm060. Epub 2007 Jun 25.
Human complement factor H (CFH) is a plasma glycoprotein involved in the regulation of the alternative pathway of the complement system. A deficiency in CFH is a cause of severe pathologies like atypical haemolytic uraemic syndrome (aHUS). CFH is a 155-kDa glycoprotein containing nine potential N-glycosylation sites. In the current study, we present a quantitative glycosylation analysis of CFH using capillary electrophoresis and a complete site-specific N-glycan characterization using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) and liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESIMS/MS). A 17.9-kDa mass decrease, observed after glycosidase treatment, indicated that N-glycosylation is the major post-translational modification of CFH. This mass difference is consistent with CFH glycosylation by diantennary disialylated glycans of 2204 Da on eight sites. CFH was not sensitive to endoglycosidase H (Endo H) deglycosylation, indicating the absence of hybrid and oligomannose structures. Quantitative analysis showed that CFH is mainly glycosylated by complex, diantennary disialylated, non-fucosylated glycans. Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified. MS analysis allowed complete characterization of the protein backbone, verification of the glycosylation sites and site-specific N-glycan identification. The absence of glycosylation at Asn199 of the NGSP sequence of CFH is shown. Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864. Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified. Interestingly, the sialylation level along with the amount of triantennary structures decreases from the N- to the C-terminal side of the protein.
人补体因子H(CFH)是一种血浆糖蛋白,参与补体系统替代途径的调节。CFH缺乏是导致严重疾病的原因,如非典型溶血性尿毒症综合征(aHUS)。CFH是一种155 kDa的糖蛋白,含有9个潜在的N-糖基化位点。在本研究中,我们使用毛细管电泳对CFH进行了定量糖基化分析,并使用基质辅助激光解吸/电离飞行时间(MALDI-TOF)和液相色谱-电喷雾电离串联质谱(LC-ESIMS/MS)对完整的位点特异性N-聚糖进行了表征。糖苷酶处理后观察到17.9 kDa的质量下降,表明N-糖基化是CFH主要的翻译后修饰。这种质量差异与CFH在8个位点被2204 Da的双触角二唾液酸化聚糖糖基化一致。CFH对内切糖苷酶H(Endo H)去糖基化不敏感,表明不存在杂合和寡甘露糖结构。定量分析表明,CFH主要被复杂的、双触角二唾液酸化的、非岩藻糖基化的聚糖糖基化。还鉴定出了二唾液酸化岩藻糖基化和单唾液酸化非岩藻糖基化寡糖。质谱分析能够对蛋白质骨架进行完整表征,验证糖基化位点并鉴定位点特异性N-聚糖。结果显示CFH的NGSP序列中Asn199处不存在糖基化。Asn511、Asn700、Asn784、Asn804、Asn864、Asn893、Asn1011和Asn1077主要被双触角二唾液酸化结构糖基化,相对分布在Asn804的45%至Asn864的75%之间变化。还鉴定出了双触角单唾液酸化聚糖以及三触角三唾液酸化岩藻糖基化和非岩藻糖基化结构。有趣的是,从蛋白质的N端到C端,唾液酸化水平以及三触角结构的数量均降低。